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The aims of this study were to investigate the premarket assessment of autologous chondrocyte im-
plantation (ACI) products especially regarding the non-clinical assessment by surveying the guidelines
and review reports of authorized ACI products in detail and to provide information regarding the non-
clinical assessment of the safety and efﬁcacy for the future development of regenerative medicine
products to design effective premarket assessment. The non-clinical assessment plays a role in justifying
the testing of investigational products in humans. Effective non-clinical assessments minimize the risk of
clinical trials and achieve prompt product development. In this study, we focused on authorized ACI
products that remain in the body of patients for a long time and often contain extrinsic components such
as animal tissue-derived collagen.
We summarized the details of the characteristics of each ACI product, non-clinical assessment design
and related guidelines. To design effective non-clinical assessments, we discussed the evaluation method
(particularly the validation of clinical assessment and mechanical property testing), the employed animal
models, and the differences in the assessment of the safety and efﬁcacy of the products.
Based on these investigations, we provide the details of satisfactory non-clinical assessment of ACI
products and indicate the possibility of more effective non-clinical assessment of ACI products and other
future regenerative medicine products.
© 2015, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V. All
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The clinical testing of novel human cell and tissue products such
as regenerative medicinal products is generally based on non-
clinical assessment programs that span the discovery-phase and
proof-of-concept (POC) studies to deﬁnitive safety studies.
Non-clinical assessments play a role in justifying the testing of
investigational products in humans and facilitate prompt product
development. Non-clinical assessment should help facilitate the
following: ﬁrst, establish the scientiﬁc rationale of the proposed
approach; second, identify, characterize, and minimize potential
local and systemic toxicities; third, conﬁrm a safe initial clinical
starting dose, dose-escalation scheme and dosing regimen; and
fourth, inform subject eligibility and clinical evaluation strategies
[1].
Recently, we published the research paper on regulation of
allogeneic human cells and tissue products [2] and on autologoussting by Elsevier B.V. All rights reserved.
Table 1
The list of abbreviations.
Abbreviation Description
ACI Autologous Chondrocyte Implantation
CAT Committee for Advanced Therapy
CBER Center for Biologics Evaluation and Research
CDRH Center for Devices and Radiological Health
CHMP Committee for Medicinal Products for Human Use
CMC Chemistry, Manufacturing, and Control
DMEM Dulbecco's Modiﬁed Eagle's Medium
ECM Extra Cellular Matrix
EMA European Medicines Agency
EU European Union
FDA Food and Drug Administration
ICRS International Cartilage Research Society
INDs Investigational New Drug Applications
JP Japan
MA Massachusetts
MHLW Ministry of Health Labour and Welfare
PMDA Pharmaceuticals and Medical Device Agency
PF Periosteal Flap
PF/AuCC Periosteal Flap/Autologous Cultured Chondrocyte
POC Proof-of-Concept
US United States
T. Ikawa et al. / Regenerative Therapy 1 (2015) 98e108 99human cells and tissue products [3]. However, there is no such
detail of non-clinical assessment of autologous human cells and
tissue products, especially of autologous chondrocyte implantation
(ACI) products.
Four ACI products have been authorized in the United States
(US), the European Union (EU) and Japan since 1997 until 2013. The
ACI products remain inside the body of patients for a long time as
implants. Therefore, the risks should be assessed and understood as
much as possible, although redundant assessment is not desirable
for the applicants and patients. For this reason, keeping the number
of assessments low is important for ensuring that the assessments
are safe and effective for patients.
In addition, the National Diet of Japan passed Revised Pharma-
ceutical Affairs Law in 2014. According to the revised law, a thera-
peutic product for regenerative medicine is deﬁned as a product
distinct from pharmaceuticals and medical devices, enabling
regenerative medical products to be given a conditional, time-
limited marketing authorization much earlier than that under the
previous system [4] Conditional, time-limited marketing authori-
zation system is expected that it makes quick patients' access to
novel therapy, however, there were concerns that the clinical safety
of a product was not sufﬁciently conﬁrmed by the early authori-
zation, so the more effective preclinical assessments that clearly
conﬁrm the proof of concept and address the adverse events would
be required than in the previous system.
The aims of this study were to investigate the premarket
assessment of ACI products especially regarding the non-clinical
assessment by surveying the guidelines and review reports of
authorized ACI products in detail and to provide effective infor-
mation on the safety and efﬁcacy for the future development of
regenerative medicine products.
2. Methods
2.1. Guidelines for premarket assessment
This study included four ACI products approved in the US, the
EU and Japan before April 2014.
To understand the requirements of the regulatory agencies in
each nation, we surveyed the following guidelines of premarket
assessment related to knee repair cartilage products: “Guidance for
Industry Preparation of IDEs and INDs for Products Intended to
Repair or Replace Knee Cartilage” [5] and “Guidance for FDA Re-
viewers and Sponsor Content and Review of Chemistry,
Manufacturing, and Control (CMC) Information for Human Somatic
Cell Therapy Investigational New Drug Applications (INDs)” [6] by
the Food Drug Administration (FDA), “Guideline on human cell-
based medicinal products (EMA/CHMP/410869/2006)” [7] and
“Reﬂection paper on in-vitro cultured chondrocyte containing
products for cartilage repair of the knee” (EMA/CAT/CPWP/568181/
2009)” [8] by the European Medicines Agency (EMA), “The evalu-
ation index of medical device in next generation (Evaluation index
about regeneration of articular cartilage)” [9] and “Ensuring the
safety and quality of human autologous cell-based or tissue-based
pharmaceutical or medical device” [10] by the Ministry of Health
Labour and Welfare (MHLW).
2.2. Authorized ACI products
To survey the details of non-clinical assessments of each prod-
uct, we surveyed the review reports or public assessment reports
for premarket assessment. The summary of the basis of approval of
Carticel® [11], review report by JACC [12] and the European Public
Assessment Reports (EPAR) on ChondroCelect™ [13] and MACI®
[14] were obtained from the appropriate web sites of the FDA, theEMA and the Pharmaceuticals and Medical Device Agency (PMDA),
respectively. The details of the assessments were surveyed
regarding the type of assessment, the animal model and the
duration and method of assessment. The type of assessment was
classiﬁed as “Pharmacodynamics”, “Pharmacokinetics”, “Mechani-
cal property” and “Validation of clinical evaluation” for pharma-
cology, and “Local toxicity”, “Systemic toxicity”, “Tumorigenicity”
and “Genotoxicity” for toxicology. The abbreviation of this article is
listed in Table 1.
3. Results
3.1. Characteristics of ACI products
The therapeutic indication for all products was cartilage defects
of the knee. In addition, the indication was limited to the femoral
condyle in the case of Carticel® and ChondroCelect™ especially. The
recommended lesion size of each product was different: 1e5 cm2,
>4 cm2 and 3e20 cm2 in ChondroCelect™, JACC, MACI®, respec-
tively. In the case of Carticel®, the recommended lesion sizewas not
described. The cell numbers of each product are shown in Table 2.
Regarding the product component, the ACI products contained an
extrinsic component such as medium and/or a collagen compo-
nent. The autologous chondrocytes of JACCwere subjected to three-
dimensional culture in authorized bovine dermis-derived atelo-
collagen to retain the implanted cells within the lesion. Similarly,
MACI® contained a collagen component; the cells in MACI® were
seeded onto a CE-marked porcine type I/III collagenmembrane, and
the membrane was secured into the lesionwith porcine ﬁbrin glue.
On the other hand, the Carticel® and ChondroCelect™ contained
only Dulbecco's modiﬁed Eagle's medium (DMEM) as an extrinsic
component (Table 2).
3.2. History of regulatory action of ACI products
There have been several issuances of guidelines related to
authorized ACI products.
The ﬁrst issuance regarding ACI products was “Guidance on
Applications for Products Comprised of Living Autologous Cells
Manipulated Ex Vivo and Intended for Structural Repair or Recon-
struction; Availability” [15] in May 1996 (Fig. 1 (a)) in the US. The
Table 2
Authorized Autologous Chondrocyte Implantation products.
Generic name (Trade
name)
Marketing authorization holder Authority Therapeutic indication Product formation
Autologous cultured
chondrocyte
(Carticel®)
Genzyme Tissue Repair,
Cambridge, MA, US
FDA/CBER (1997) Use for signiﬁcant, symptomatic,
cartilaginous defects of the femoral
condyle (medial, lateral or
trochlear) caused by acute or
repetitive trauma
Each single use vial has
approximately 12 million cells
aseptically processed and
suspended in 0.4 mL of sterile,
buffered DMEM
Autologous cultured
chondrocyte
(ChondroCelect™)
TiGenix N.V., Romeinse straat,
Leuven, Belgium
EMA/CAT/CHMP (2009) Use for 1e5 cm2 single
symptomatic cartilage defects of
the femoral condyle of the knee in
adults.
Package as one falcon tube of
product contains
approximately 4 million human
autologous cells in 0.4 mL the
suspension contains cells and
excipients DMEM
Human autologous
implantation tissue
(JACC)
Japan Tissue Engineering Co.,
Ltd., Gamagori, Aichi, Japan
PMDA/Ofﬁce of Biologics II
(2012)
Use for more than 4 cm2 cartilage
defect (traumatic cartilage defect or
osteochondritis dissecans) of the
knee
Package as the cell were three-
dimensionally cultured in
atelocollagen gel and contains
4.5  104 cells
Matrix applied
characterized
autologous cultured
chondrocytes
(MACI®)
Genzyme Europe B.V.,
Gooimeer, Naarden,
Netherlands
EMA/CAT/CHMP (2013) Use for 3e20 cm2 full-thickness
cartilage defects of the knee of in
skeletally mature adult patients
Package as the implantation
matrix consists of characterized
autologous chondrocytes on a
14.5 cm2 Type I/III collagen
membrane, at a density of 0.5
million to 1 million cells per
cm2 and 18 mL colourless
solution in a dish
MA, Massachusetts; US, the United States; FDA, Food and Drug Administration; CBER, Center for Biologics Evaluation and Research; DMEM, Dulbecco's. Modiﬁed Eagles
Medium; EMA, European Medicines Agency; CAT, Committee for Advanced Therapy; CHMP, Committee for Medicinal Products for Human Use; PMDA, Pharmaceutical and
Medical Device Agency.
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by the FDA. In addition, Carticel®was also deﬁned as a manipulated
autologous structural cell product in the above guideline.
In 2007, the “Guideline on human cell-based medicinal prod-
ucts” (EMA/CHMP/410869/2006) [7] was released by the EMA for
the manufacture and quality control of human somatic cell therapy
medicinal products. The application of ChondroCelect™ was sub-
mitted to the EMA in June 2007 (Fig. 1 (d)) and was authorized in
June 2009; the duration between the application and the authori-
zation was only two years.
A reﬂection paper focusing on the repair of cartilage lesions of
the knee was released by the EMA in October 2010 (Fig. 1 (e)) and
was titled “Reﬂection paper on in-vitro cultured chondrocyte
products for cartilage repair of the knee” (EMA/CAT/CPWP/568181/
2009) [8]. This reﬂection paper was a supplement of the EMA/
CHMP/410869/2006, and the reﬂection paper should be evaluated
in conjunction with the guideline. In the same period, the JACC
application was submitted to the PMDA in August 2009, and was
authorized in June 2012. It took almost three years from application
to market. Around the regulatory review process of JACC, the
guidelines “The evaluation index for medical devices in the next
generation (Evaluation index for the regeneration of articular
cartilage)”[9] and “Ensuring safety and quality of human autolo-
gous cell-based or tissue-based pharmaceutical or medical device”
[10] were released in December 2010 (Fig. 1 (f)) and September
2012 (Fig. 1 (g)), respectively by the MHLW to accelerate and
conﬁrm the quality of premarket assessment and the review of
novel products.
There has been no authorization of ACI products in the US after
the authorization of Carticel® in 1996 [5]. A guideline documents
were released in April 2008 and December 2011 (Fig. 1 (b), (c)) to
provide information on CMC and premarket assessment that
should be included in the application for products intended to knee
cartilage. MACI® was the most recently authorized by the EMA in
April 2013. Prior to the premarketing authorization, the product has
been available in some European countries since 1998.3.3. Guidelines and reﬂection paper on ACI products
We summarized several indices described in the guidelines and
reﬂection papers in Table 3.
The assessments of the pharmacodynamics were described in
all of the documents. Both the EMA and the FDA represented the
recommended animal models as large animals such as goat, sheep
and horse in each document. The large animals have similar char-
acteristics to that of humans in terms of size, form and thickness of
the articular cartilage [16]. In the MHLW guideline, a histological
evaluationmethod such as O'Driscoll scoring,Wakitani scoring, and
International Cartilage Research Society (ICRS) scoring method was
recommended. In addition, the assessment of durability was
especially described as pharmacodynamics only in the FDA docu-
ment. The resistance to wear and degradation and the ability to
withstand physiologically relevant loads over time for a minimum
of one year should be conﬁrmed by testing with large animal
models such as goat, sheep and horse.
Regarding the assessment of mechanical properties, the
assessment based on the static/dynamic loading and ﬁxation
method etc. was recommended in all of the documents by all of the
agencies of the EMA, the FDA and the MLHW. The recommended
method of assessment was the measurement of the typical pa-
rameters such as maximum recoverable compressive strain, the
aggregate modulus, the shear modulus and the permeability in the
FDA document.
The assessment of pharmacokinetics (biodistribution) was
described in the guidelines of all agencies to evaluate the inﬂuences
of the ectopic location for the cell and surrounding tissues. In the
documents of the EMA and the MHLW, the conventional testing of
pharmacokinetics, that includes absorption, migration, meta-
bolism, excretion, etc., were described to assess the inﬂuence of
undesirable cell migration and the persistence of the cells and
components. In the FDA guideline, the conventional pharmacoki-
netics were not described in particular, although the assessment of
the degradation of the product in the joint and the cell or particle
Fig. 1. Regulatory action regarding approved autologous chondrocyte implantation
(ACI) products. In the US, “Guidance on Applications for Products Comprised of Living
Autologous Cells Manipulated Ex Vivo and Intended for Structural Repair or Recon-
struction; Availability” was released in May 1996 and Carticel® was subsequently
approved in August 1997 (a). As the next action, “Guidance for FDA Reviewers and
Sponsors Content and Review of Chemistry, Manufacturing, and Control (CMC) Infor-
mation for Human Somatic Cell Therapy Investigational New Drug Applications (INDs)“
was released in April 2008 (b). The latest action was the issuance of the guidelines
“Guidance for Industry Preparation of IDEs and INDs for Products Intended to Repair or
Replace Knee Cartilage” in December 2011 (c). In the EU, the “Guideline on human cell-
based medicinal products” (EMA/CHMP/410869/2006) was released in January 2007
(d), and the application of ChondroCelect™ was submitted to the EMA in June 2007
and authorized in October 2009. The reﬂection paper focused on the repair of
cartilage lesions of the knee was released in the EMA in April 2010 (e) for the sup-
plement of EMA/CHMP/410869/2006 and was named “Reﬂection paper on in-vitro
cultured chondrocyte containing products for cartilage repair of the knee” (EMA/
CAT/CPWP/568181/2009). Latest ACI product was the MACI® authorized in June 2013.
In Japan, the application of JACC was submitted to the PMDA in August 2009 and was
authorized in July 2012. During the JACC authorization processes the guidance, “The
evaluation index for medical device in next generation (Evaluation index about
regeneration of articular cartilage)” (f) and “Ensuring the safety and quality of human
autologous cell-based or tissue-based pharmaceutical or medical device” (g) by the
Ministry of Health Labour and Welfare (MHLW).
References: (a) US Food and Drug Administration. Guidance on Applications for
Products Comprised of Living Autologous Cells Manipulated Ex Vivo and Intended for
Structural Repair or Reconstruction; Availability. Fed Regist. 1996; 61 FR 26523, May
28, 1996. (b) US Food and Drug Administration. Guidance for FDA Reviewers and
Sponsors Content and Review of Chemistry, Manufacturing, and Control (CMC) Infor-
mation for Human Somatic Cell Therapy Investigational New Drug Applications (INDs),
April 2008. (c) US Food and Drug Administration. Guidance for Industry Preparation of
IDEs and INDs for Products Intended to Repair or Replace Knee Cartilage. December
2011. (d) The European Medicines Agency. Guideline on human cell-based medicinal
product. EMEA/CHMP/410869/2006, January 2007. (e) The European Medicines
Agency. Reﬂection paper on in-vitro cultured chondrocyte containing products for
cartilage repair of the knee. EMA/CAT/CPWP/568181/2009, April 2010. (f) The Ministry
of Health Labour and Welfare. The evaluation index for medical device in next gen-
eration (Evaluation index about regeneration of articular cartilage). Yakushokuki-hatsu
1215 No.1, December 2010. (g) The Ministry of Health Labour and Welfare. Ensuring the
safety and quality of human autologous cell-based or tissue-based pharmaceutical or
medical device. Yakushokuki-hatsu 0907 No.2, September 2012.
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Systemic toxicology.
Other assessments related to pharmacology such as “Dose
response” and “Lesion size and location” that should be validated
for the condition andmethod of clinical assessment were described
only in the FDA document.
The EMA and FDA documents recommended a validating MRI
method as structural endpoints. The MHLW indicated the use of a
scoring method such as ICRS scoring, O'Driscoll scoring orWakitani
scoring for an appropriate histological evaluation method.Subsequently, regarding the toxicology, the assessment of local
toxicology that was the interaction between the implanted cells
and the surrounding tissue and degradation were recommended in
the documents of the all of the agencies.
The EMA and MHLW guidelines stated that local toxicity as
based on the assessment of the tissue compatibility and the inﬂu-
ence between the cells or surrounding tissue and the non-cellular
structural components or other bioactive molecules should be
assessed.
The assessment of systemic toxicity was recommended in the
documents of all of the agencies. The FDA guideline described the
evaluation of the inﬂuence caused by cell or particle migration
outside of the articular space. In the MHLW document, the
biocompatibility of reabsorption was described. In the EMA docu-
ment, the systemic inﬂuence was not described as the toxicology
but as the safety pharmacology.
In addition, it was recommended that the single and repeated
toxicology assessment for local/systemic toxicology should be
combined with safety pharmacology, local tolerance, or proof of
concept and efﬁcacy studies in EMA/CHMP/410869/2006.
The assessment of tumorigenicity was described in the FDA,
EMA and MHLW documents. The EMA document indicated that
cells for assessment should be at the limit of routine cell culture or
even beyond that limit in EMA/CHMP/410869/2006. The FDA
document represented the necessity of assessment of tumorige-
nicity and the inappropriate differentiation of cellular products
exists within or outside of the articular space. In the MHLW
guidelines, the conventional assessments of tumorigenicity for
example, karyotype analysis, soft-agar colony formation assay and
injection in knocked-out mice, and undesirable transformation or
overgrowth should be described.
The assessment of genotoxicity was described only in the EMA
guidelines, which stated that it should be evaluated only in cases in
which the product directly inﬂuences DNA or other chromosomal
material.
3.4. Non-clinical ACI assessment
The approved ACI products were investigated in 26 studies for
non-clinical assessment. We summarized each study including the
animal model, duration of study and the method of evaluation
(Table 4). The number of studies referenced by previous reporting
was 2/3, 0/5 and 5/9 for the Carticel®, JACC and MACI® products,
respectively. In the case of ChondroCelect™, the number of animals
was not speciﬁed in the review report.
Small animal models, such as mice and rabbits, were applied for
all of the products as the ﬁrst in vivo proof of study. Carticel®, JACC
and MACI® were investigated in 2, 1 and 2 studies using rabbits,
respectively. The proof of study for ChondroCelect™ only was
assessed in small animals by the injection of human cells into nude
(immunodeﬁciency) mice to directly evaluate the behavior of hu-
man cells.
Large animal models, e.g., dog, goat, sheep and horse were used
to mimic as closely as possible the mechanical conditions in
humans. The assessment using large animals was performed with
dog for Carticel®, sheep and goat for ChondroCelect™, dog for JACC,
and sheep and horse forMACI®. The duration of the assessmentwas
more than one year for all products (the longest study was study
No.23 for 18 months). The histological evaluation in large animals
can be more similar to that in humans than in small animals.
Additionally, the assessment usingMRI was applied only for MACI®.
The scoring method assessed the condition of the implanted
cells, and the surrounding tissue or extra cellar matrix (ECM) such
as collagen type II histologically was not the same for each product.
O'Driscoll scoring, Modiﬁed O'Driscoll scoring, Wakitani scoring
Table 3
The guidelines for the assessment of pharmacology and toxicology for ACI in the EU, US and Japan.
Name of guidelines Type of assessment Animal model Duration post treatment Content of assessment
Guideline on human
cell-based medicinal
products, EU, 2007
and Reﬂection paper
on in-vitro cultured
chondrocyte
containing products
for cartilage repair of
the knee, EU, 2010
Pharmacodynamics  Goat, sheep, horse and
other appropriate animal
(mini pig, cow etc.)
 The number of animals in
studies should allow for
robust analysis
 Long enough (Not speciﬁed)  Initial proof of study with in vitro cell
culture
 First in vivo proof of study, (small
animal study, large animal number)
 Pivotal non-clinical study (large
animal)
Ex) Proof of regeneration and repair
Biodistribution/
Pharmacokinetics
 Relevant animal model
(Consideration that
product is not sufﬁciently
physically retained)
N.D.  To demonstrate the cell alteration
due to the factors in the new
environment
Mechanical property N.D.  Long enough (Not speciﬁed)  The long pivotal study should include
testing for biomechanical property
Validation of clinical
evaluation
N.D.  Long enough (Not speciﬁed)  Validation of MRI method as
structural endpoint, Proof of
regeneration and repair
Local/Systemic
Toxicology
 Relevant animal model  Much longer than standard
toxicity study.
 To demonstrate the interaction with
surrounding normal tissue
 The study may be combined with
efﬁcacy study.
Ex) Single and repeated toxicity and
Local
Tolerance, etc.
Tumorigenicity N.D. N.D.  To perform with cells that are at the
limit of routine cell culture or even
beyond that limit.
 Tissues found to contain applied cells
or expressed products during the
biodistribution studies should also be
analyzed with special emphasis
during tumorigenicity studies.
Genotoxicity N.D. N.D.  Genotoxicity should be evaluated
only in the case in which a product
directly inﬂuences DNA or other
chromosomal material.
Guidance for FDA
Reviewers and
Sponsors Content
and Review of
Chemistry,
Manufacturing, and
Control (CMC)
Information for
Human Somatic Cell
Therapy
Investigational New
Drug Applications
(INDs), US, 2008 and
Guidance for
Industry Preparation
of IDEs and INDs for
Products Intended to
Repair or Replace
Knee Cartilage, US,
2011
Pharmacodynamics  Large animal (Goat,
Sheep and Horse)
 The number of studies
 Appropriate number is
relevant structural and
biological characteristics
of the product
 Minimum of one year  Biological response
To demonstrate that a product's
components have the potential to
contribute to the clinical efﬁcacy
 Durability
To evaluate the ability of resistance of
wear, degradation, withstand
physiological relevant loads over time,
etc.
 Dose response
To assess the dose response with cell
number, material constituent etc. as
anatomic and biomechanical
considerations
Biodistribution/
Pharmacokinetics
N.D. N.D.  Lesion size and location
To assess the mimicking what will be
studied clinically
Mechanical property N.D. N.D.  To assess the withstand static/
dynamic loading, method of ﬁxation,
Validation of clinical
evaluation
N.D. N.D.  To reduce the number of animal
sacriﬁces at each time point, it may
be appropriate to provide interim
validate the MRI or arthroscopic
assessment.
Local/Systemic
Toxicology
N.D. N.D.  Local: interaction and degradation
 Systemic: Migration
Tumorigenicity N.D. N.D.  Potential for tumorigenicity or
inappropriate differentiation of
cellular products exists within or
outside of the articular space.
The evaluation index of
medical device in
next generation
(Evaluation index
about regeneration
of articular
cartilage), Japan,
2010 and Ensuring
the safety and
Local/Systemic
Toxicology
N.D. N.D.  Local: interaction and degradation
Systemic: Migration
Tumorigenicity N.D. N.D.  Potential for tumorigenicity or
inappropriate differentiation of
cellular products exists within or
outside of the articular space.
Mechanical property N.D. N.D.  To test the viscoelastic property,
compatibility of load bearing, sliding
property
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Table 3 (continued )
Name of guidelines Type of assessment Animal model Duration post treatment Content of assessment
quality of human
autologous cell-
based or tissue-
based
pharmaceutical or
medical device,
Japan, 2012
Local/Systemic
Toxicology
N.D. N.D.  Local: To demonstrate the interaction
with surrounding normal tissue, no
undesirable transformation of the cell
 Systemic: To assess the degradation,
reabsorption and potential of
ectopic tissue formation
Tumorigenicity  Knock-out animal
(Injection)The model
without chromosomal
aberration is favorable
(Karyotype)
N.D.  To test the incidence of tumor and
hypertrophy (Karyotype analysis,
Injection, Soft-agar analysis)
Immunogenicity N.D. N.D.  To assess the undesirable
immunoreaction caused by product
or expression of cytokine
N.D.: not described.
US, the United States; EU, the European Union; ACI, Autologous Chondrocyte Implantation; MRI, Magnetic resonance imaging; ICRS, International Cartilage Repair Society.
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for Carticel®, ChondroCelect™, JACC and MACI®.
In addition, several assessments that were performed by the
applicant, Carticel®, JACC and MACI®, included both pharmacology
and toxicology in study No. 1, 13, 14, 24 and 25 in Table 4.
In Carticel®, non-clinical assessments included pharmacody-
namics, biodistribution and local toxicity. In particular, study No. 1
included both pharmacodynamics and local toxicity, and study No.
3 included pharmacodynamics and biodistribution.
All of the ChondroCelect™ studies were assigned to each single
property. This was different from other products, in which each
assessment included several properties.
In the JACC, mainly the property of safety was assessed.
Tumorigenicity was assessed with three assessments, and all safety
properties were evaluated with more than two assessments. In
addition, two studies, No. 13 and 14, included pharmacodynamics,
local toxicity and systemic toxicity.
MACI® included the properties and the highest number of as-
sessments of the four products. Almost all properties were assessed
except the tumorigenicity. The karyotype was assessed in the
genotoxicity assessment, but tumorigenicity was not assessed.
The studies from No.18 to No. 25 were performed for pharma-
codynamics, and 5 of these studies (No. 18, 20e23) were referred to
from previous studies. Two studies, No. 24 and No. 25, were per-
formed by the applicant and tested several properties simulta-
neously including the biodistribution, the mechanical properties,
the validation of clinical evaluation, the local toxicity and the sys-
temic toxicity. In addition, almost all of the safety properties were
assessed by the applicant except in the No. 25 and No. 26 studies for
genotoxicity that were also referred studies.
4. Discussion
4.1. The EU products
ChondroCelect™ was approved by the EMA before the issuance
of the reﬂection paper (EMA/CAT/CPWP/568181/2009), and MACI®
was approved after this paper was issued. ChondroCelect™ and
MACI® were approved in 2009 and 2013, respectively, and the
reﬂection paper was released in 2010. There were several charac-
teristic differences in the assessments between ChondroCelect™
and MACI®.
First, the assessments mimicked as much as possible the
routine in humans (such as the MRI evaluation) and should bevalidated in the reﬂection paper. In the non-clinical study of
ChondroCelect™, clinical evaluations such as MRI were not
performed at all. Basically, the evaluation of an implanted lesion
included the euthanasia and histological assessment with tissue
staining such as O'Driscoll score or Modiﬁed O'Driscoll score
only. The macroscopic evaluation such as MRI or arthroscopy
evaluation was not performed in ChondroCelect™. On the other
hand, macroscopic evaluation such as MRI with a scoring method
was applied to assess the percent ﬁlling, the surface smoothness,
repair tissue integration (hyaline-like cartilage and ﬁbro-
cartilage) and pannus formation in MACI®. Although the valida-
tion of MRI evaluation was recommended in the reﬂection paper,
it was performed only in one study by Jones et al., 2008 [17]
involving MACI®. MRI was recommended as a non-invasive
method that is free from known morbidity and is safer and less
expensive for clinical use; it is a common and effective method
for evaluating articular tissue. However, an important factor is
that MRI evaluation was limited by the high-cost faculty involved
and by the technical nature of the procedure, especially for large
animals. On the other hand, other methods of evaluation such as
arthroscopy can be performed without the need for exceptional
faculty.
In another aspect, the non-invasive method of MRI evaluation
was recommended for clinical use although non-clinical study
should be performed in the more invasive condition than that of a
clinical trial based on the guidelines for nonclinical assessment
[18,19].
Both arthroscopy and MRI were the major methods and should
be validated. Therefore, it may be important to conﬁrm and discuss
the issue of practical use, for instance, in reference to the previous
studies, the availability of other faculty and the possibility of
combining clinical data with non-clinical data.
Second, the mechanical property was important in particular
for the cartilage products, although few assessments contained
this property in the case of ChondroCelect™ and MACI®. There
was also the recommendation in the paper (EMA/CAT/CPWP/
568181/2009) such as including the testing for biomechanical
properties in a pivotal non-clinical study. Only in the MACI®, this
property was assessed by the applicant (in No. 25 study) using
aggregate modulus, hydraulic permeability, frictional properties
of repair cartilage and the strength of the interface between
repaired tissue and surrounding cartilage etc.
It was assumed that it was more difﬁcult to assess these me-
chanical parameters in a clinical study especially in detail.
Table 4
Non-clinical assessments of Pharmacology and Toxicology.
Generic name (Trade
name)
Study no. Type of assessment The model/number of
animal
Time point The method of assessment
Autologous cultured
chondrocyte
(Carticel®)
1  Pharmacodynamics
 Local toxicity
 Dogs
 20 dogs
6, 13, 26, 52 weeks To evaluate the longevity of the implanted cell
ﬁlling of hyaline-like cartilage or ﬁbro cartilage,
and injury of the subchondral bone (5 dogs/
time-point)
2a  Pharmacodynamics  Rabbits
 20 rabbits
6 weeks To evaluate the short-term activity of PF versus
PF/AuCC treatment
Residence time and total contribution of cells
(Half is control)
3b  Pharmacodynamics
 Pharmacokinetics
 Rabbits
 24 rabbits
8,12, 52 weeks To evaluate the quality of repair in chronic non-
weight-bearing (patellar) cartilage defects
Filling of hyaline-like cartilage and cell
distribution
O'Driscoll scoring (7e12 rabbits/time-point)
Autologous cultured
chondrocyte
(ChondroCelect™)
4  Pharmacodynamics  Nude mice
 N.A.
2 weeks To assess the formation of hyaline-like nature
intramuscular injection vs. human normal adult
articular cartilage, Hyaline-like nature
(Histological staining)
5  Pharmacodynamics  Nude mice N.A. To compare the formation of cartilage tissue
between late passage and Early passage,
Implantation of human chondrocyte (Early
passage expanded/late passage expanded cells)
6  Pharmacodynamics  Goats
 N.A.
53 weeks To assess an improved repair in the defect
center, and improved repair tissue integration
by Modiﬁed O'Driscoll scoring (Differentiated/
Dedifferentiated chondrocyte)
7  Pharmacodynamics  Goats
 N.A.
53 weeks To assess the mobility and the degree of ﬁlling
with hyaline-like cartilage and ﬁbro cartilage
8  Pharmacokinetics  Goats
 N.A.
N.A. To assess the persistence of cells in the inﬂicted
cartilage defect because of the potential
migration of cells by the ﬂuorescence-tagged
cells
9  Local/Systemic
toxicity
 NMRI nu/nu mice
 N.A.
N.A. To assess the single or concomitant use of
heterologous cells by intra muscular or
subcutaneous injection (human, pig, goat)
10  Local toxicity  Sheep
 N.A.
N.A. To validate the ChondroCelect culture process
by the penetration to subchondral bone
11  Local toxicity  Goats
 N.A.
N.A. To assess inﬂammation and ectopic cartilage or
bone formation in the synovium and synovial
ﬂuid by the macroscopic, histological and
biochemical composition
12  Tumorigenicity  In vitro (Human
chondrocyte)
 N.A.
N.A. To assess the immortalization of human
chondrocytes during limited time in in vitro
culture conditions
Human autologous
implantation tissue
(JACC)
13  Pharmacodynamics
 Local/Systemic
toxicity
 Rabbits (Allogeneic
chondrocyte
implantation with
periosteal ﬂap,
collagen gel with
periosteal ﬂap, with
periosteal ﬂap only)
 60 rabbits
28, 56, 84, 168, 371
days
To assess the degree of repair, local and
systemic toxicity based on hematologic testing,
blood chemical analysis, histopathological
evaluation, histological evaluation (Wakitani
scoring)
14  Pharmacodynamics
 Local/Systemic
toxicity
 Dogs
 36 dogs
26, 53 weeks To assess degree of repair, local and systemic
toxicity by hematologic testing, blood
chemical analysis, histological evaluation
(Wakitani scoring)
15  Tumorigenicity
(Injection)
 Nude mice (Seeded
with 1x107cells/
mouse)
 20 mice
N.A. To assess the implantation into subcutaneous of
nude mice (late passage, early passage)
16  Tumorigenicity (soft-
agar colony
formation)
 In vitro (Chondrocyte,
MRC-5, HeLa)
N.A. To assess the colony formation and trans
formation
17  Tumorigenicity
(Karyotype)
 In vitro (Pre-
passaging, post-
passaging)
N.A. To assess the chromosomal aberration by
Giemsa staining and G-band staining technique
Matrix applied
characterized
autologous cultured
chondrocytes
(MACI®)
18c  Pharmacodynamics  Rabbits
 16 rabbits
6, 12 weeks To assess time course experiment and Dose-
response experiment using ICRS scoring
19 GENZ 06-0147  Pharmacodynamics  Rabbits
 20 rabbits
12, 24 weeks To assess clinical relevant (Shallower defect),
inﬂuence of two defects in one animal using
Scoring system described by Sellers et al.d
20e  Pharmacodynamics  Sheep
 27 sheep
4, 12 months To assess the efﬁcacy of product with or without
the parallel use of MF using O'Driscoll scoring
and Pineda scoring (Empty defect with no MF,
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Table 4 (continued )
Generic name (Trade
name)
Study no. Type of assessment The model/number of
animal
Time point The method of assessment
empty defect with MF, cell-free membrane with
MF and chondrocyte seeded collagen
membrane)
21f  Pharmacodynamics  Sheep
 21 sheep
8, 10, 12 weeks To assess the efﬁcacy of product and validation
of evaluation method
ICRS scoring and biomechanical compression
analysis
Detecting by MRI and confocal arthroscopy
(Untreated controls, treatment with MACI,
treatment with membrane only)
22g  Pharmacodynamics  Horses
 15 horses
3, 12 months To assess the efﬁcacy in more similar model
using
Modiﬁed O'Driscoll scoring and arthroscopy
(MACI-like product, membrane only or were
left empty)
23h  Pharmacodynamics  Horses
 15 horses
3, 6, 12,18 months To examine efﬁcacy of femoral cartilage defect
repair using a MACI-like implant
Modiﬁed O0 Driscoll scoring (after sacriﬁcing)
24 GENZ 06-0239  Pharmacodynamics
 Local/Systemic
toxicity
 Horses (Seeded with
0.9e1.1  106 cells)
 6 horses
3 (not sacriﬁced), 6
months
To assess the histological property of cartilage,
chondrocyte predominance and Collagen type II
formation
At 3 month post treatment: second-look
arthroscopy with scoring of the defect areas,
blood characterization and synovial tissue
biopsy
At 6 months post treatment: sacriﬁced and
repair was analyzed by gross observation,
histology, immunohistochemistry (type II
collagen) and biochemical analysis
25 GENZ 09-4417  Pharmacodynamics
Pharmacokinetics
 Local/Systemic
toxicity
 Mechanical property
 Horses
 27 horses
53 weeks To assess the histological property of cartilage,
Chondrocyte predominance and Collagen type
II formation and
Treatment with MACI in 1 defect and cell-free
membrane in the other defect, Treatment with
MACI in 1 defect and the other defect was left
empty, No treatment in either defect and served
as untreated controls
26 GENZ RR07030  Genotoxicity  In vitro N.A. The karyotype of chondrocytes was evaluated at
various stages of culture.
N.A.: not available.
ICRS, International Cartilage Repair Society; PO, Periosteal Flap; PO/AuCC, Periosteal Flap/Autologous Cultured Chondrocyte.
a Grande DA, Pitman MI, Peterson L, Menche D, Klein M., The repair of experimentally produced defects in rabbit articular cartilage by autologous chondrocyte trans-
plantation J Orthop Res. 1989; 7(2):208e18.
b Brittberg M, Nilsson A, Lindahl A, Ohlsson C, Peterson L. Rabbit articular cartilage defects treated with autologous cultured chondrocytes. Clin Orthop Relat Res.1996 May;
(326): 270e83.
c Willers C, Chen J, Wood D, Xu J, Zheng MH., Autologous chondrocyte implantation with collagen bio-scaffold for the treatment of osteochondral defects in rabbits. Tissue
Eng. 2005; 11(7e8):1065e76.
d Sellers RS, Zhang R, Glasson SS, Kim HD, Peluso D, D'Augusta DA et al. Repair of articular cartilage defects one year after treatment with recombinant human bone
morphogenetic protein-2 (rhBMP-2). J Bone Joint Surg Am. 2000; 82(2):151e60.
e Dorotka R, Bindreiter U, Macfelda K, Windberger U, Nehrer S., Marrow stimulation and chondrocyte transplantation using a collagen matrix for cartilage repair. Osteo-
arthritis Cartilage. 2005; 13(8):655e64.
f Jones CW, Willers C, Keogh A, Smolinski D, Fick D, Yates PJ et al. Matrix-induced autologous chondrocyte implantation in sheep: objective assessments including confocal
arthroscopy. J Orthop Res. 2008; 26(3):292e303.
g Not described in the European Public Assessment Reports.
h Frisbie DD, Bowman SM, Colhoun HA, DiCarlo EF, Kawcak CE, McIlwraith CW. Evaluation of autologous chondrocyte transplantation via a collagen membrane in equine
articular defects: results at 12 and 18 months. Osteoarthritis Cartilage. 2008; 16(6):667e679.
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clinical assessment. The detailed histological assessment and dose
response may also be evaluated in non-clinical assessment for
similar reasons.
Therefore, we showed two characteristic differences in each
previous and subsequent issuance of the reﬂection paper (EMA/
CAT/CPWP/568181/2009). The conducting the assessments
mimicked the routine in humans and the performing the me-
chanical assessments. The inﬂuence of the reﬂection paper can be
considered because the two properties and the use of large animals
were recommended in the reﬂection paper (EMA/CAT/CPWP/
568181/2009).4.2. Animal model
Several types of animal models were applied in each product,
and the usage of large animal was recommended by the agencies. In
the FDA and EMA, goat, sheep and horse were recommended
especially because the tissue size and available lesion size were
more similar to those of humans [16]. It was also important to keep
the number of animals low due to the ﬁnancial cost and animal
ethical considerations.
The number of animals used in the non-clinical assessment of
each product is shown in Fig. 2 except for ChondroCelect™ because
of the lack of information for the number of animals with that
Fig. 2. Animal numbers for the non-clinical assessment. These ﬁgures indicate the
number of animals for the non-clinical assessment of each autologous chondrocyte
implantation (ACI) product. These numbers were referred from each the review report,
European Public Assessment Reports (EPAR) or the summary for the basis of approval.
The number of animals from both the referenced studies and the studies performed by
the applicants were exhibited. Carticel® had 20 and 44 animals from the referenced
studies and the studies by the applicant, respectively, whereas in JACC, 116 animals
from studies by the applicant only were involved. MACI® had the largest number of
animals for non-clinical assessments; 94 and 53 animals were quoted as the referenced
studies and the studies by the applicant, respectively. In the case of ChondroCelect™,
there was no detail information regarding the numbers of animals in the EPAR (N.D.:
no data available) although sheep and goat were used in the studies by the applicant.
T. Ikawa et al. / Regenerative Therapy 1 (2015) 98e108106product. The lower side of the broken line in Fig. 2 indicates the
referenced study, and the upper-side indicates the study by the
applicant. Fig. 2 shows that the non-clinical assessments of JACC
had no referenced studies in the review report. The applicant
performed all of the non-clinical assessments in their own studies.
On the other hand, for the MACI®, 94 of the total of 147 animals
were applied in referenced studies, and this was 2 times that
involved in the studies performed by the applicant. Additionally, all
of the studies were performed for the authorized application in
JACC (Fig. 2). Of course, the referred studies were available to enrich
the database and provide evidence of assessment and were also
important to supplement assessments that were difﬁcult for the
actual applicant to evaluate.
The data from previous studies should be considered and
investigated to keep the number of animals low although no study
can completely replace an objective study.
In another aspect, the number of pre-approval clinical uses of
Carticel®, ChondroCelect™, JACC and MACI® should be considered.
In particular, theMACI®was available in certain European, Australia
and parts of Asian countries since 1998, and more than 5000 pa-
tients were treated since 2005 when the applicant started a safetyTable 5
The comparison between guideline documents and product assessments.
Guidance documents/products Pharmacology
Pharmacodynamics Biodistribution/
Pharmacokinetics
Mechani
property
Guideline of the EU ✔a ✔ ✔
Guideline of the US ✔ ✔ ✔
Guideline of Japan ✔ ✔ ✔
Carticel® ✔ ✔ e
ChondroCelect™ ✔ ✔ e
JACC ✔ eb e
MACI® ✔ ✔ ✔
EU, European Union; US, United States; JP, Japan.
a ✔: Described.
b e: Not described.reporting system before the application [14]. However, the safety
reporting system data were not applied even as clinical data for the
application. On the other hand, the pre-approval clinical use of
ChondroCelect™ for example, expanded access and compassionate
use was applied as clinical safety data. The design of non-clinical
assessment should be optimized. For instance, the non-clinical
assessment that can be performed for mechanical properties, his-
tological properties or tumorigenicity would be preferentially
performed, and the assessments would be omitted or decreased for
the properties that were assessed for pre-approval clinical use such
as the potential risk of long-term use or the validation of a clinical
imaging method such as MRI if the applicant had enough evidence
based on experience with pre-approval marketing.
4.3. Safety and efﬁcacy of non-clinical assessments
It was important to administer the risk retained in the clinical
trial during non-clinical assessment. One objective of non-clinical
assessments is conﬁrming and decreasing the risks for clinical tri-
als. Better conﬁrmation is based on assessments that investigated
various relevant properties of the product in detail. In this study,
the detailed guidelines and non-clinical assessment are repre-
sented in Tables 3 and 4, respectively, and we attempted to sum-
marize the coverage of the guidelines and non-clinical assessments
performed by the applicant in Table 5. This indicates how widely
and deeply the applicant considers the risks required by the
agencies. In addition, these results can show the difference in the
test conditions among similar products. Fewer properties for risks
can be evaluated in early products than in late products, and non-
clinical assessment that included previously revealed risks should
be designed for late products. Assessments that evaluated too
widely and deeply are not preferable.
In the ﬁrst ACI product, Carticel®, the non-clinical assessments
were performed for the fewest properties, pharmacodynamics, and
local toxicity for safety. There were no appropriate guidelines or
indications for the non-clinical assessment of chondrocyte prod-
ucts when the premarket evaluation for Carticel® was conducted.
Consequently, the potential risks must be higher than the later
products. Actually, adverse events such as “graft failure,” “delami-
nation” and “tissue hypertrophy” were commonly reported, and
these three adverse events accounted for almost 65% of all adverse
events [20]. In addition, these adverse events can be reduced by
evaluating the extra assessments for “Mechanical property” and
“Dose response” using a large animalmodel that has articular tissue
that is more similar to that in humans. These extra assessments
were recommended as pharmacodynamics in the guidelines of the
agencies released after the authorization of Carticel®.
In the ChondroCelect™, the coverage of assessments was more
than that in Carticel® in terms of “Systemic toxicity” andToxicology
cal Validation of
clinical evaluation
Local
toxicity
Systemic
toxicity
Tumorigenicity Genotoxicity
✔ ✔ ✔ ✔ ✔
✔ ✔ ✔ ✔ e
e ✔ ✔ ✔ e
e ✔ e e e
e ✔ ✔ ✔ e
e ✔ ✔ ✔ ✔
✔ ✔ ✔ e ✔
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toxicity” was performed with knocked-out mice and intramuscular
or subcutaneous injections of human cells based on the evaluation
of death or health, and “Local toxicity” was assessed based on the
evaluation of penetration to subchondral bone and ectopic cartilage
as well as bone formation in the synovium and synovial ﬂuid.
The JACCwas authorized three years later from ChondroCelect™
and covered almost same properties as ChondroCelect™ except
“Biodistribution”. However, the content of the assessment of “Local/
Systemic toxicity” was more detailed than for the analysis of he-
matologic testing, blood chemical analysis, analysis of organweight
and histopathological evaluation for ChondroCelect™. The assess-
ment of “Local/Systemic toxicity” was also applied to the blood
characterization analysis. It was considered that only JACC and
MACI contain animal derived collagen component among the
target ACI products.
In the MACI®, assessments were conducted for various proper-
ties, and the risks conﬁrmed most of the details of the target
products. The assessment of large animals, such as sheep and
horses, and the assessment of “Mechanical property” or “Validation
for clinical evaluation” were important for the preclinical assess-
ment of safety. However, in the case of MACI®, several clinical
studies were performed before the authorized application, and the
MACI® clinical safety data were referred to the adverse event data
from previous studies; in addition, there were pre-authorization
data from the clinical use in more than 5000 patients from 2005
in the applicant's safety reporting system, so that the clinical risks
were assessed before the non-clinical assessment based on several
reported adverse events. Therefore, the necessity and amount of
non-clinical assessment should be designed considering the data
from the premarket clinical use or non-clinical study. For the
MACI®, the premarket clinical use data were only for safety, so that
it was considered that “Pharmacodynamics” was mainly tested in
non-clinical assessment.
The scientiﬁc rationale of the proposed approach should also be
conﬁrmed in the non-clinical assessment as efﬁcacy. Among the US,
the EU and Japan, the content of the guidelines regarding efﬁcacy
was similar as represented in Table 5. The types of assessment for
“Pharmacodynamics”, “Biodistribution” and “Mechanical property”
were described in the guidelines of all of the agencies. In particular,
the “Pharmacodynamics” was described in detail regarding the
recommended assessment condition. The animal model was rec-
ommended by applying large animal models such as sheep, goat
and horse in the EMA and FDA documents. Long-term assessment
was preferable for safety. Only in the FDA document, the duration of
assessment was speciﬁed, as the recommendation was more than
one year. In addition, the proof of biological response, durability
and dose response was required in the “Pharmacodynamics”
guidelines of the US and Japan. It was assumed that the “Pharma-
codynamics” for efﬁcacy was one of the most important properties
especially in the ACI products that have preauthorization clinical
use such as Carticel®, ChondroCelect™ and MACI® because these
products have already hadmore clinical data for the safety than the
data for efﬁcacy.
The conditions of product assessments for “Pharmacodynamics”
for efﬁcacy seemed to almost satisfy the requirements from the
agency based on the guidelines even in the products authorized
before the releasing guidelines such as Carticel® except for the
animal models and dose response studies. The efﬁcacy or non-
recessive property was conﬁrmed. The assessment of “Pharmaco-
dynamics” of the ﬁrst authorized ACI product, Carticel®, was con-
ducted on rabbit and dog based on a histological scoring evaluation
regarding the ﬁlling of hyaline-like cartilage and ﬁbrocartilage
simply for 52 weeks at the most, whereas the latest product, MACI®
was conducted with sheep and horse for 18 months, which is themost by histological scoring evaluation regarding the formation of
tissue and extra cellular matrix (ECM) such as collagen type II. In
MACI®, the treatment and observation were often conducted using
MRI/arthroscopy. The guidelines for ACI product indicated that the
duration was preferable for more than one year to evaluate the
durability, and also indicated that the evaluation should contain the
proof of regeneration and repair.
In addition, from above, the condition of assessment of MACI®
became more similar to the condition of the clinical trials than the
ﬁrst product, Carticel®.
The applicants of each product and the agencies referred to the
data from previous products. The amount of safety data increased
since the ﬁrst product, Carticel®. Therefore, the requirements of the
agencies increase similarly. However, we currently show the min-
imum requirements for the non-clinical assessments of future ACI
products.
In the US, the requirement of additional assessments and the
details of assessment would be based on the current released
guidelines for ACI products as shown in Table 3 because the prod-
ucts have not been approved since the authorization of Carticel®. In
the EU, the latest product, MACI®, was approved in 2013. The
package of assessments would be based on that of MACI® as shown
in Table 4. Particularly, the use of MRI and arthroscopy for the
histological evaluation and the lack of “Tumorigenicity” were
characteristic. In Japan, the assessments of safety were referred to
that of JACC because the assessments shown in Table 4 such as
“Systemic toxicity” and full “Tumorigenicity” of JACC were among
the characteristics of the non-clinical assessments in Japan. The
necessity of these assessments should be discussed.
Additionally, the assessments that can be conducted simulta-
neously would be conducted in one study. For example, in the as-
sessments of the latest product, MACI®, “Pharmacodynamics”,
“Biodistribution”, “Mechanical property” and “Local/Systemic
toxicity” were conducted in one study as shown in the MACI®’s
study (GENZ 09e4417) (Table 4) because these assessments were
performed with the similar histological evaluations.
Therefore, the minimum requirements would be the pivotal
studies with small animals and large animals containing the as-
sessments of “Pharmacodynamics”, “Biodistribution”, “Mechanical
property” and “Local/Systemic toxicity” to conﬁrm the safety and
efﬁcacy systemically and in detail because these assessments are
conducted in almost all products or is necessary to conﬁrm the
fundamental character of the ACI product. The assessments of
“Tumorigenicity” and “Genotoxicity”would be added as required in
the discussion because there have been no adverse events related
to ”Tumorigenicity” and “Genotoxicity” of Carticel®.
5. Conclusions
In this study, we surveyed the guidelines and details of the non-
clinical assessment of ACI products, and we compared the details of
the summary for basis, the EPAR and the review reports for ACI
products authorized in different years and the guidelines of ACI
products to conﬁrm the satisfaction and transition of assessments
and to consider aspects of an effective non-clinical assessment.
Based on the results, we indicated that the practical and strict
conditions and the priority of assessment for non-clinical assess-
ment should be considered. In addition, the experience of
premarket clinical use or previous animal studies should be
considered to achieve the effective non-clinical assessment design.
Regarding the efﬁcacy, the conditions of product assessments
seemed to almost satisfy the requirements from the agency as
described in the guidelines even for products authorized before the
release of the guidelines, except the animal model especially in
terms of “Pharmacodynamics.” Regarding safety, the assessment of
T. Ikawa et al. / Regenerative Therapy 1 (2015) 98e108108MACI® conﬁrmed the most risks among the target products. We
indicated the possibility of using pre-authorization clinical use data
to reduce the number of unnecessary non-clinical assessments.
Therefore, we indicated the details and satisfaction of non-
clinical assessments for ACI products and concluded that investi-
gation of more effective non-clinical assessment of ACI products
and other future regenerative medicine products will be of great
help for development of regenerative medicine. In addition, we
represented the possible minimum requirement of the non-clinical
assessments for ACI products as the pivotal studies with small
animals and large animals involving the fundamental assessments
to conﬁrm the safety and efﬁcacy systemically and in detail because
these assessments are conducted in almost all products or are
necessary to conﬁrm the fundamental character of the ACI product.
The assessments of “Tumorigenicity” and “Genotoxicity” would be
added as required under the discussion because there have been no
adverse events related to these two assessments.
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